Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy plus chemo takes on rare brain cancer

NCT ID NCT06475235

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy can safely treat newly diagnosed primary central nervous system lymphoma. The trial will enroll 15 adults and primarily look for serious side effects, while also checking how well the cancer responds. It is an early-stage study at Dana-Farber Cancer Institute.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pembrolizumab (Keytruda) combined with methotrexate, temozolomide, and rituximab
What this could lead to
If it works, this could point toward a more effective treatment for primary CNS lymphoma, potentially improving remission rates.
What could go wrong
This is a very early Phase 1 pilot study with only 15 participants, focused on safety. It may not show clear benefit, and the drug combination could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma of the central nervous system lymphoma primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.